羟基脲预防镰状细胞病患儿脑损伤(HU Prevent)——一项随机、安慰剂对照的II期可行性/先导研究
HU Prevent是一项随机(1:1)、双盲、II期可行性/先导试验,纳入12-48月龄、神经系统检查、脑MRI和脑血流速度正常的HbSS或HbS-β0地中海贫血型镰状细胞病患儿,比较剂量递增羟基脲与安慰剂对中枢神经系统损伤的一级预防作用。每组随机6例;羟基脲组1例发生主要结局 vs 安慰剂组4例(发生率比[90%CI] 0.216[0.009, 1.66],p=.2914),羟基脲组约降低80%。
要点
- 羟基脲组主要结局1例 vs 安慰剂组4例,发生率比0.216(90%CI 0.009-1.66),p=.2914。
- 卒中后果风险评分均值羟基脲组0.078(SD 0.174) vs 安慰剂组0.312(SD 0.174),p=.072。
- 41次MRI中3次发生与研究操作相关的严重不良事件,均与镇静相关。
核心结论
- 结果提示羟基脲可能对镰状细胞病患儿具有深远神经保护作用,并支持开展确定性III期研究以鼓励所有镰状细胞病婴儿早期使用羟基脲。
研究设计与样本
- 随机(1:1)、双盲、II期可行性/先导试验,比较剂量递增羟基脲与安慰剂对中枢神经系统损伤的一级预防。
- 纳入12-48月龄、神经系统检查、脑MRI和脑血流速度正常的HbSS或HbS-β0地中海贫血型镰状细胞病患儿,每组随机6例。
主要发现
- 主要结局(无症状脑梗死、脑血流速度升高、短暂性脑缺血发作或卒中的复合结局)羟基脲组1例 vs 安慰剂组4例,发生率比(90%CI)0.216(0.009, 1.66),p=.2914,羟基脲组约降低80%。
- 卒中后果风险评分(SCRSS)均值羟基脲组0.078(SD 0.174) vs 安慰剂组0.312(SD 0.174),p=.072。
- 41次MRI中3次发生与研究操作相关的严重不良事件,均与镇静相关。
关键数值与推荐
- 主要结局发生率比(90%CI)0.216(0.009, 1.66),p=.2914。
- 卒中后果风险评分均值羟基脲组0.078(SD 0.174) vs 安慰剂组0.312(SD 0.174),p=.072。
临床怎么用
- 原文结论支持开展确定性III期研究以鼓励所有镰状细胞病婴儿早期使用羟基脲。
局限性
- 原文报告每组仅随机6例。
- 主要结局发生率比90%CI为0.009至1.66,跨1,未达统计学显著。
- 卒中后果风险评分组间比较p=.072,低于常用于支持后续III期研究的p=.10阈值。
- 原文报告41次MRI中3次发生与研究操作相关的严重不良事件,均与镇静相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Central nervous system (CNS) injury is common in sickle cell disease (SCD) and occurs early in life. Hydroxyurea is safe and efficacious for treatment of SCD, but high-quality evidence from randomized trials to estimate its neuroprotective effect is scant. HU Prevent was a randomized (1:1), double-blind, phase II feasibility/pilot trial of dose-escalated hydroxyurea vs. placebo for the primary prevention of CNS injury in children with HbSS or HbS-β0-thalassemia subtypes of SCD age 12-48 months with normal neurological examination, MRI of the brain, and cerebral blood flow velocity. We hypothesized that hydroxyurea would reduce by 50% the incidence of CNS injury. Two outcomes were compared: primary-a composite of silent cerebral infarction, elevated cerebral blood flow velocity, transient ischemic attack, or stroke; secondary-a weighted score estimating the risk of suffering the consequences of stroke (the Stroke Consequences Risk Score-SCRS), based on the same outcome events. Six participants were randomized to each group. One participant in the hydroxyurea group had a primary outcome vs. four in the placebo group (incidence rate ratio [90% CI] 0.216 [0.009, 1.66], p = .2914) (~80% reduction in the hydroxyurea group). The mean SCRS score was 0.078 (SD 0.174) in the hydroxyurea group, 0.312 (SD 0.174) in the placebo group, p = .072, below the p-value of .10 often used to justify subsequent phase III investigations. Serious adverse events related to study procedures occurred in 3/41 MRIs performed, all related to sedation. These results suggest that hydroxyurea may have profound neuroprotective effect in children with SCD and support a definitive phase III study to encourage the early use of hydroxyurea in all infants with SCD.
引用
- Casella JF, Furstenau DK, Adams RJ, et al. Hydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)-A randomized, placebo-controlled phase II feasibility/pilot study. Am J Hematol. 2024. PMID: 38953438. doi:10.1002/ajh.27423
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。